The FTC also ordered that Shkreli’s firm, Vyera Pharmaceuticals, which was created in 2015 and was responsible for boosting the price of Daraprim, must repay the $64.6 million in earnings from the price increase. Vyera has paid the FTC its $40 million commitment, but Shkreli has failed to pay his part of $24.6 million.
Shkreli has been seeking to form a firm “that looks to be involved in the pharmaceutical sector” since July 2022, according to documents presented to the FTC on Friday. Druglike, according to reports, aims to “eliminate obstacles to early-stage drug research, enhance creativity, and allow a larger number of contributors to enjoy the profits.”
